{{Rsnum
|rsid=10883783
|Gene=CYP17A1
|Chromosome=10
|position=104591152
|Orientation=plus
|GMAF=0.2236
|Gene_s=CYP17A1,CYP17A1-AS1
|Assembly=GRCh37.p10
|GenomeBuild=37.5
|dbSNPBuild=138
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 7.9 | 46.0 | 46.0
| HCB | 2.2 | 40.0 | 57.8
| JPT | 0.0 | 27.3 | 72.7
| YRI | 1.6 | 12.7 | 85.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 2.2 | 40.0 | 57.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20503394
|Title=CYP17 polymorphisms and prostate cancer outcomes
|OA=1
}}{{PMID Auto
|PMID=16782804
|Title=Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females.
|OA=1
}}

{{PMID Auto
|PMID=18163429
|Title=Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
|OA=1
}}

{{PMID Auto
|PMID=19567509
|Title=Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.
|OA=1
}}